EMA committee recommends approval of AstraZeneca's Truqap plus Faslodex for patients with advanced ER─positive breast ...
AstraZeneca’s Truqap (capivasertib) in combination with Faslodex (fulvestrant) has been recommended for approval in the European Union (EU) for the treatment of adult patients with estrogen receptor (ER)-positive, HER2-negative locally advanced or …